Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEGALOGUE vs ZEGALOGUE (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older,Off-label: Not specified
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.
Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment.
50–65 minutes (terminal elimination half-life).
Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved.
Primarily metabolized via proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%).
Primarily hepatic metabolism followed by biliary and fecal excretion, with negligible renal elimination (<2%).
Approximately 85% bound to albumin and alpha-1-acid glycoprotein.
Negligible (<5%); not significantly bound to plasma proteins.
0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma.
0.3–0.5 L/kg, indicating distribution primarily in extracellular fluid.
Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%.
100% after intramuscular injection (autoinjector).
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (e GFR <15 m L/min/1.73 m2) due to lack of data.
No dosage adjustment required for renal impairment.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients.
No dosage adjustment required for hepatic impairment.
Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established.
Weight-based dosing: 0.01 mg/kg IM (maximum 0.25 mg) into the anterolateral thigh, repeated once after 15 minutes if necessary.
No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status.
No specific adjustment required; monitor for adverse effects due to potential comorbidities.
None.
None
Risk of serious hypersensitivity reactions including anaphylaxis,May cause nausea and vomiting,Risk of hypoglycemia if used in patients with insulinoma or glucagonoma,May increase blood pressure and heart rate
Risk of hypoglycemia due to overdose or inadequate response,Risk of nausea and vomiting,Risk of hypersensitivity reactions including anaphylaxis,Risk of hyperglycemia in patients with pheochromocytoma or insulinoma
Pheochromocytoma,Insulinoma,Known hypersensitivity to dasiglucagon or any excipients
Known hypersensitivity to dasiglucagon or any component of the formulation,Pheochromocytoma (risk of hypertensive crisis),Insulinoma (risk of hypoglycemia)
No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery.
No specific food interactions. However, after successful treatment, patients should consume fast-acting carbohydrates to stabilize blood glucose levels and prevent recurrent hypoglycemia.
Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated.
Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the MRHD. Risk cannot be ruled out; use only if clearly needed. First trimester: limited data; theoretical risk of hyperglycemia-related effects if maternal hypoglycemia not corrected. Second and third trimesters: same as first; no known teratogenicity.
No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia.
No data on dasiglucagon in human milk; excretion unknown. Glucagon is a peptide with low oral bioavailability; unlikely to be absorbed by infant. M/P ratio not available. Consider risk/benefit; monitor infant for hypoglycemia.
No pharmacokinetic data in pregnancy; dosing adjustments not recommended. Use standard dose (0.6 mg) for severe hypoglycemia regardless of trimester.
No pharmacokinetic data in pregnancy; dose adjustment not recommended based on current evidence. Administer 0.6 mg as single subcutaneous dose regardless of gestational age. Monitor for recurrence of hypoglycemia; repeat dosing may be considered if needed.
ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature.
Zegalogue (dasiglucagon) is a glucagon analog indicated for severe hypoglycemia in diabetes patients aged 6 years and older. It is administered via autoinjector into the lower abdomen, outer thigh, or outer upper arm. Unlike reconstituted glucagon, it is stable in liquid form, allowing for rapid administration without reconstitution. Onset of action is within 10-15 minutes. Patients may experience nausea and vomiting; risk can be reduced by lying patient on side to prevent aspiration. Ensure patient has received carbohydrate intake once conscious to prevent recurrent hypoglycemia.
Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious.,Inject into buttock, thigh, or abdomen; no need to mix or reconstitute.,After injection, call emergency services immediately.,Administer supplemental carbs (if conscious and can swallow) after blood glucose responds.,Common side effects: nausea, vomiting, headache, injection site pain.,Store at controlled room temperature (20-25°C); do not freeze.
Use only for severe hypoglycemia where the patient is unable to take oral carbohydrates.,Inject into the lower abdomen, outer thigh, or outer upper arm through clothing if necessary.,Do not use if the solution is discolored or contains particles.,After injection, call emergency medical services immediately.,Turn patient on their side to prevent choking if vomiting occurs.,Once conscious, give fast-acting sugar (e.g., fruit juice, glucose tablets) to prevent recurrence.,Store at room temperature; do not freeze or expose to heat above 30°C (86°F).,Check expiration date before use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZEGALOGUE vs ZEGALOGUE (AUTOINJECTOR), answered by our medical review team.
ZEGALOGUE is a GnRH Antagonist that works by ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.. ZEGALOGUE (AUTOINJECTOR) is a GnRH Antagonist that works by Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZEGALOGUE and ZEGALOGUE (AUTOINJECTOR) depend on the specific clinical indication. These are both GnRH Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZEGALOGUE is: Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.. The standard adult dose of ZEGALOGUE (AUTOINJECTOR) is: 0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZEGALOGUE and ZEGALOGUE (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZEGALOGUE is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk c. ZEGALOGUE (AUTOINJECTOR) is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.